Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- w6 K: {6 i t6 l
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
6 C7 p/ b$ A- Q. x0 s4 Y# ^+ Author Affiliations
& _5 R) B9 `5 y- L! [+ n: k2 o0 }$ P$ Q+ Q
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
; }7 G* V! N7 o) S ]( V2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 S4 _# l' w8 o3 h
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 @+ t3 g. }4 k; Q/ ]4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
, f2 @) Y+ f. d2 Y- ` Q! J8 J h5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 3 P) }" v: S" G
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
" {5 U7 b8 {0 @' ^7Kinki University School of Medicine, Osaka 589-8511, Japan % r/ v$ J7 m9 F7 ?
8Izumi Municipal Hospital, Osaka 594-0071, Japan 9 ]2 R4 z) c0 c* U F
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( x8 a+ S# t @1 ?! NCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp # ^) ?8 H. `; ~. A8 T/ S) d, t
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
6 P' k) `+ |& d X- U( C6 ?7 V% q) V$ H! _ k
|